Exploiting Cancer metabolism for drug discover
Speaker: Dr Frances Byrne, Cancer Institure NSW Early Career Fellow
This seminar will describe the development of a phenotypic drug screen to identify novel small molecules that alter cell metabolism and are selectively toxic to cancer cells. The basis for this drug screen was the knowledge that most genetic aberrations that initiate and promote cancer development in one way or another regulate cell metabolism. Not surprisingly, dysregulated metabolism is recognised as a hallmark of cancer and potential vulnerability by which to target cancer cells. From this screen a lead molecule was discovered that displays better cancer cell-specific toxicity than many frontline chemotherapy agents and molecules known to target cancer metabolism. Metabolomics and metabolic flux experiments helped determine how this molecule induces cancer cell death and selective toxicity. Working alongside medicinal chemists has led to the development of new molecules, with improved pharmacokinetics and oral bioavailability that may facilitate translational into the clinic.
Followed by Happy Hour in Wilton Tearoom 113, Level 1, Samuels Building F25